Financial reports
10-Q
2024 Q1
Quarterly report
11 Mar 24
NT 10-Q
Notice of late quarterly filing
15 Feb 24
10-K
2023 FY
Annual report
19 Jan 24
NT 10-K
Notice of late annual filing
2 Jan 24
10-Q
2023 Q3
Quarterly report
17 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q2
Quarterly report
30 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-Q
2023 Q1
Quarterly report
13 Feb 23
10-K
2022 FY
Annual report
9 Jan 23
Current reports
8-K
Other Events
13 Nov 23
8-K
Changes in Registrant's Certifying Accountant
27 Jun 23
8-K
Globestar Therapeutics Enters into Mou with Advanced Innovative Partners to Develop Clinical Studies for Multiple Sclerosis Treatment
22 Jun 23
8-K
Other Events
6 Apr 23
8-K
Unregistered Sales of Equity Securities
11 Apr 22
8-K
Regulation FD Disclosure
12 Oct 21
8-K
Regulation FD Disclosure
4 Oct 21
8-K
Multiple Sclerosis Drug Development Information September 2021
20 Sep 21
8-K
AngioSoma, Inc. Adds Brooke Greenwald As Chief Marketing Officer
6 May 21
8-K
Regulation FD Disclosure
5 May 21
Registration and prospectus
S-8
Registration of securities for employees
27 Apr 17
8-A12G
Registration of securities
30 Sep 13
S-8
Registration of securities for employees
16 Mar 12
S-1/A
IPO registration (amended)
11 Feb 11
S-1/A
IPO registration (amended)
31 Jan 11
S-1/A
IPO registration (amended)
28 Dec 10
S-1
IPO registration
3 Nov 10
Proxies
DEF 14A
Definitive proxy
23 Sep 19
PRE 14A
Preliminary proxy
9 Sep 19
SC 14F1
Statement regarding change in majority of directors
6 Jun 16
DEF 14A
Definitive proxy
8 Apr 15
PRER14A
Preliminary revised proxy
31 Mar 15
PRER14A
Preliminary revised proxy
24 Mar 15
PRER14A
Preliminary revised proxy
27 Feb 15
PRE 14A
Preliminary proxy
22 Jan 15
Other
UPLOAD
Letter from SEC
9 Apr 15
UPLOAD
Letter from SEC
16 Mar 15
UPLOAD
Letter from SEC
12 Feb 15
UPLOAD
Letter from SEC
10 Dec 12
CORRESP
Correspondence with SEC
19 Oct 12
UPLOAD
Letter from SEC
17 Sep 12
CORRESP
Correspondence with SEC
11 Feb 11
EFFECT
Notice of effectiveness
11 Feb 11
CORRESP
Correspondence with SEC
8 Feb 11
UPLOAD
Letter from SEC
14 Jan 11
Ownership